Overcoming HIV-1 resistance to protease inhibitors

Research output: Contribution to journalReview articlepeer-review

19 Scopus citations


Protease inhibitors are key components in the chemotherapy of HIV-1 infection. However, despite their success, the appearance of viral mutations routinely compromises their clinical efficacy, creating a constant need for new and better inhibitors. An ideal inhibitor should be able to neutralize the wild type as well as mutants associated with drug resistance with high potency and high selectivity towards human targets, thus minimizing side effects. The evolution of protease inhibitors since 1995 has revealed the basis for extremely high affinity as well as different mechanisms by which inhibitors can escape the deleterious effects of mutations.

Original languageEnglish (US)
Pages (from-to)281-286
Number of pages6
JournalDrug Discovery Today: Disease Mechanisms
Issue number2
StatePublished - 2006

ASJC Scopus subject areas

  • Molecular Medicine
  • Drug Discovery


Dive into the research topics of 'Overcoming HIV-1 resistance to protease inhibitors'. Together they form a unique fingerprint.

Cite this